Projected Health Benefits and Costs of Pneumococcal and Rotavirus Vaccination in Uganda
The authors of this article, published in Vaccine, determined the impact and cost-effectiveness of pneumococcal and rotavirus vaccination programs among children younge than five years of age in Uganda from the public health system perspective. They used disease-specific models to compare the disease burden and cost with and without a vaccination program. The results indicated that, at the GAVI Alliance price of US$0.15/dose, pneumococcal vaccine will be cost-saving and rotavirus vaccine will be highly cost-effective. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Tate JE, Kisakye A, Mugyenyi P, Kizza D, Odiit A, Braka F
Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Tate JE, Kisakye A, Mugyenyi P, Kizza D, Odiit A, Braka F. Projected Health Benefits and Costs of Pneumococcal and Rotavirus Vaccination in Uganda. Vaccine. 2011;29(17):3329-3334.